RA Capital Healthcare Fund LP's Form 4 filing
Vor Biopharma Inc. (VOR) · filed Oct 17, 2025
- Accession no.
- 0001231919-25-000333
- Filed
- Oct 17, 2025, 6:03 PM ET
- Trade date
- Oct 15-17, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 16 non-derivative transactions. Open-market sales total $13.7M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | Common Stock | SSaleDisposed | −42,699 | $30.55F1 | −$1,304,454.45 | 1,848,336 | Indirect | |
| Oct 15, 2025 | Common Stock | SSaleDisposed | −8,384 | $30.55F1 | −$256,131.2 | 82,882 | Indirect | |
| Oct 15, 2025 | Common Stock | SSaleDisposed | −234 | $31.17F6 | −$7,293.78 | 1,848,102 | Indirect | |
| Oct 15, 2025 | Common Stock | SSaleDisposed | −46 | $31.17F6 | −$1,433.82 | 82,836 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −111,041 | $29.32F7 | −$3,255,722.12 | 1,737,061 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −21,804 | $29.32F7 | −$639,293.28 | 61,032 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −15,826 | $30.36F8 | −$480,477.36 | 1,721,235 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −3,108 | $30.36F8 | −$94,358.88 | 57,924 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −20 | $31.35 | −$627 | 1,721,215 | Indirect | |
| Oct 16, 2025 | Common Stock | SSaleDisposed | −4 | $31.35 | −$125.4 | 57,920 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −174,594 | $29.12F9 | −$5,084,177.28 | 1,546,621 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −34,284 | $29.12F9 | −$998,350.08 | 23,636 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −30,758 | $30.28F10 | −$931,352.24 | 1,515,863 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −6,040 | $30.28F10 | −$182,891.2 | 17,596 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −12,691 | $31.00 | −$393,421 | 1,503,172 | Indirect | |
| Oct 17, 2025 | Common Stock | SSaleDisposed | −2,492 | $31.00 | −$77,252 | 15,104 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.15 to $31.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.17 to $31.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.695 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.80 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.70 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
Remarks
Ms. Sarah Reed, General Counsel of the Adviser, serves on the Issuer's board of directors.